VivoSeq
Other

NSCLC Stage III

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

NSCLC Stage III is an early-stage landscape with 0 programs across 1 company. The most active players are Hellenic Oncology Research Group.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hellenic Oncology Research Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Completed4 · 80%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV
Completed·HHellenic Oncology Research Group·Phase 2·NCT00614965·124 enrolled
Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV
Completed·HHellenic Oncology Research Group·Phase 2·NCT00615758·50 enrolled
Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT00198393·126 enrolled
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04351256·51 enrolled
Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III
Completed·NNational Taiwan University Hospital·Phase 2·NCT00172380·41 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)